Medtronic launches new device in U.S. to improve treatment of aortic aneurysm
High blood pressure can be a trial of patience for doctors and for sufferers, whose blood pressure often has to be monitored over a long time until it can be regulated. This will now be made easier by a pressure sensor that is inserted in the femoral artery. If a person’s blood flows through their
Full Post: Tiny pressure sensor in artery measures blood pressure
Adding to its recent endovascular aortic repair (EVAR) innovations, Medtronic, Inc. has announced the U.S. launch of the Talent Abdominal Stent Graft on the Xcelerant Hydro Delivery System.
EVAR is a treatment for aortic aneurysm, a dangerous bulge or weakening in the body’s main artery that can rupture with fatal consequences if left untreated. In the United States, abdominal aortic aneurysms - the most common type - are responsible for approximately 15,000 deaths annually. Worldwide, it is estimated that more than one million people are living with undiagnosed aortic aneurysms, and that 95 percent of these could be successfully treated if detected before rupture.
EVAR involves the navigation of a stent graft, via the body’s arteries, to the aorta. The stent graft is then deployed to create a reinforced tube within the aorta, reducing pressure on the aneurysm and the risk of rupture. EVAR is a minimally-invasive alternative to open surgical repair.
The Xcelerant Hydro Delivery System features a hydrophilic coating which attracts and holds water at the device surface to reduce friction. The coating is designed to aid navigation through the femoral and iliac arteries en route to the aorta.
“The combination of the Xcelerant Hydro Delivery System and the Talent Abdominal Stent Graft represents another major step forward for the treatment of patients with abdominal aortic aneurysms,” said Dr. Manish Mehta of Albany Medical College and Albany Medical Center Hospital in New York. “The hydrophilic coating takes deliverability to a new level and gives endovascular interventionalists like me greater control over the deployment of this excellent stent graft, which has no equal in terms of sizes and profile. Taken together, these technologies simplify the procedure and enhance patient care - a powerful combination indeed.”
“The Xcelerant Hydro Delivery System again demonstrates Medtronic’s innovation in the field of EVAR,” said Tony Semedo, vice president and general manager of Endovascular Innovations at Medtronic. “The launch of the Talent stent grafts earlier this year made EVAR available to significantly more patients than possible with earlier technologies. Now, by introducing the Talent Abdominal Stent Graft on the Xcelerant Hydro Delivery System in the United States, we have enhanced navigation. All of these innovations benefit physicians and patients alike.”
A pioneer of EVAR, Medtronic has been an innovator and leader in the stent graft industry for over a decade. Its history includes more than 150,000 patients treated with stent grafts dating back to 1995. Medtronic offers the broadest portfolio of aortic stent grafts. The AneuRx AAAdvantage and Talent Abdominal Stent Grafts with the Xcelerant Hydro Delivery System and the Talent Thoracic Stent Graft with the Xcelerant Delivery System are commercially available in the U.S. The Valiant Thoracic Stent Graft and the Endurant Stent Graft Systems are commercially available only outside the U.S. The Reliant Stent Graft Balloon Catheter is commercially available worldwide.
Minimally invasive endovascular abdominal aortic aneurysm repair (EVAR) has been praised by many vascular surgeons and patients due to its benefits: shorter operating time, reduced hospital stays, faster recovery and less scarring. It is performed through two small groin incisions rather than a large, full-length abdominal incision used in open repair. Also, EVAR is often
Full Post: Study looks at endovascular abdominal aortic aneurysm repair
Researchers have created a new family of fluorescent probes called hydrocyanines that can be used to detect and measure the presence of reactive oxygen species. Reactive oxygen species are highly reactive metabolites of oxygen that have been implicated in a variety of inflammatory diseases, including cancer and atherosclerosis. “We’ve shown that the hydrocyanines we developed
Full Post: Researchers create new family of fluorescent probes called hydrocyanines to detect reactive oxygen species in vivo
A very low risk of complication is associated with a routine test that determines whether a brain aneurysm treated with endovascular coiling has started to recur, a study led by the University of Cincinnati Neuroscience Institute has shown. The multi-site, retrospective study, published in the November issue of Neurosurgery, found a complication rate of 0.43
Full Post: Routine testing with angiography following endovascular treatment of brain aneurysms found to carry very low risk of complication
A new study suggests that patients with hepatitis C (HCV) who need a liver transplant should not receive an organ with high levels of fatty deposits (a.k.a. hepatic steatosis). HCV recurrence was more frequent and earlier among those transplanted with such livers. These findings are in the January issue of Liver Transplantation , a journal
Full Post: Transplanted fatty livers associated with worse prognosis for patients with hepatitis C
Today at the annual scientific sessions of the American Heart Association, the first U.S. clinical trial data on the Melody transcatheter pulmonary valve were presented. These findings also represent the first U.S. data on transcatheter valves in a population with congenital heart disease and the first reported U.S. data on the use of a transcatheter
Full Post: Medtronic announces U.S. trial data on transcatheter valve for congenital heart disease